|
Peru Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Peru Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Peru.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Peruvian pharmaceutical and healthcare industry.
Competitive intelligence, Peruvian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Peruvian market.
The Peru Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Peru Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Peruvian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Peru to test other views – a key input for successful budgeting and strategic business planning in the Peruvian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Peruvian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Peru.
- Exploit The Latest Competitive Peruvian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Peru.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Peru Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Peru: Pharmaceuticals And Healthcare Industry SWOT |
| Peru Political SWOT Analysis |
| Peru Economic SWOT Analysis |
| Peru Business Environment SWOT Analysis |
Chapter - Pharmaceutical Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Peru Market Summary |
| Regulatory Regime |
| Intellectual Property Regime |
| Trade Agreements |
| Counterfeit Pharmaceuticals |
| Pricing Regime |
| Government Tenders |
| Reimbursement Regime |
| Other Regulatory Issues |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Healthcare Provision |
| Health Insurance |
| Pharmaceutical Sector |
| Recent Company Activity |
| Pharmaceutical Distribution And Retail |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Table: Peru – Drug Market Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Peru – Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Peru – Economic Activity |
| Prescription Market Forecast |
| Table: Peru – Prescription Drug Market Indicators, Historical Data and Forecasts (PENmn unless otherwise indicated) |
| Patented Market Forecast |
| Table: Peru - Patented Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Peru – Generic Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: Peru – OTC Market Indicators, Historical Data and Forecasts (PENmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: Peru – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Medical Devices Forecasts |
| Table: Peru - Medical Device Market Indicators, Historical Data and Forecasts (US$mn unless otherwise indicated) |
| Other Healthcare Data Forecasts |
| Table: Peru - Other Healthcare Data Indicators, Historical Data and Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006 |
Chapter - Company Profiles |
| Leading Multinationals |
| Sanofi-Aventis |
| Merck & Co |
| GlaxoSmithKline |
| Novartis |
| Pfizer |
| AstraZeneca |
| Indigenous Manufacturer Profiles |
| Farmaindustria |
| Unimed |
| Hersil |
Chapter - Country Snapshot: Peru Demographic Data |
| Section 1: Population |
| Section 2: Education And Healthcare |
| Section 3: Labour Market And Spending Power |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Peru Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s updated Business Environment Rankings (BER) for Q209, Peru remained second-bottom in the matrix assessing ten major markets in the Americas. A small market size and a deficient intellectual property (IP) environment – including the tolerance for non-bioequivalent similares and widespread counterfeiting - represent some of the major drawbacks to the involvement of foreign companies. Nevertheless, Peru offers considerable longer-term benefits to foreign companies, not least due to its rising population numbers and solid GDP growth in recent years. A recently ratified trade agreement with the US is expected to be enforced in the course of 2009, thus leading to improvements in the intellectual property (IP) regime, but also to more intense competition to local players. In order to address such changes, local pharmaceutical manufacturers’ association announced that it plans to invest US$15mn in manufacturing and research processes in the course of 2009.
However, downward pressure on prices – largely a factor of the strong competition in the chain-dominated pharmacy retail sector and the government’s continuing support for copy and generic medicines - is likely to lead to Peru’s pharmaceutical market posting a modest compound annual growth rate (CAGR) of 6.04% in local currency terms through to 2013, though this envisages the strengthening of local currency. In 2013, the market value should reach PEN3.64bn (US$1.35bn) at consumer prices, rising from PEN2.72bn (US$0.885bn) in 2008.
In the meantime, Peru has been recording improvements in child and maternal health indicators, local press reported in February 2009 that the most recent edition of the UNICEF’s The State of the World’s Children noted that Peru has made considerable progress in reducing child and maternal deaths. According to UNICEF, childhood under-five mortality fell by 74% in the period between 1990 and 2007, although maternal mortality is still among the highest in the region. Consequently, the Ministry of Health and UNICEF-Peru have teamed up to create a maternal health project, creating new maternal waiting houses ‘Mamawasi’ in order to address problems posed by geographic distance from health services. Peru currently has some 400 Mamawasi, mostly in the highland regions, all of which are operated by local health centres or hospitals.
Other positive developments include the January 2009 introduction of stricter phytotherapeutics regulations. As South America is rich in diverse flora, the successful harnessing of biological compounds can boost the local pharmaceutical industry. The new rules are expected to create a biodiversity list or framework, which will include all of the traditional medicines used by the native population, as well as provide legal protocols for pharmaceutical firms that may be interested in finding new drugs from biomatter. Moreover, illustrating Peru’s increasing attractiveness for foreign research companies, clinical research organisation (CRO) Parexel recently opened a base in Peru's capital, Lima.
|
Peru Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |